Fennec Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company dedicated to developing and commercializing therapies for cancer patients. The company's primary product is PEDMARK® (sodium thiosulfate injection), which is the first and only FDA-approved therapy indicated to reduce the risk of cisplatin-induced ototoxicity (hearing loss) in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. Fennec operates primarily in the United States and has established strategic commercial partnerships, such as its licensing agreement with Norgine for the commercialization of PEDMARK in Europe and other international territories.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanded the commercial sales force in Q1 2026 by investing in 14 new territories and onboarding 4 frontline managers to engage more than 5,400 U.S. treatment sites.
Expected impact: Expanded the customer target base from 1,300 to over 5,000 sites, driving top-line adoption and accelerating PEDMARK® prescription volumes.
Targeting the AYA patient population through real-world clinical utility studies and investigator-initiated trials to support the integration and use of PEDMARK®.
Expected impact: Unlocks an addressable market estimated to be roughly 10 times larger than the pediatric population currently served.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Norgine is responsible for the commercialization of PEDMARQSI® in Europe, the U.K., Australia, and New Zealand, driving international expansion.
Terms: Fennec received an upfront consideration of approximately $43 million (€40 million) and is eligible to receive up to approximately $230 million (€210 million) in additional commercial and regulatory milestones, plus double-digit tiered royalties on net sales.